NY-EMPIRE-STATE-REALTY
16.6.2024 20:42:34 CEST | Business Wire | Press release
A 270-foot-long dragon has landed in the center of New York City – atop the iconic Empire State Building (ESB). In partnership with Max, ESB has acknowledged that Vhagar the Dragon has coiled herself around its mast just as ESB and Max cap off their weeklong “House of the Dragon” takeover.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240616631517/en/
Empire State Building Debuts 270-Foot Vhagar the Dragon Coiled Around the Building’s Mast, in Partnership with Max (Photo: Business Wire)
The best views of Vhagar are in Manhattan from the south of ESB, and unique selfie moments are available from ESB itself where she scans for prey with her huge head extended over the southern deck of ESB’s 86th Floor Observatory. ESB’s lights have been set so fans can witness a series of dynamic light shows which feature the dragon against schemes of gold, green, and red.
“Just after the Empire State Building pledged its allegiance to the King, Vhagar descended upon the heart of New York City and has claimed the mast of the ‘World’s Most Famous Building’ as her perch,” said ESRT Chairman and CEO Tony Malkin. “Citizens of Westeros can now sit in the Iron Throne at the Observatory’s grand staircase and then rise to the 86th Floor to face the colossal beast up close as they take in the unmatched, 360-degree views from our world-famous Observatory – Tripadvisor’s #1 attraction in the United States.”
Affixed by more than 153 rigging points, Vhagar is made up of 1,700 total patterns and 600,000 inches of sewn seams. The giant dragon was created in partnership with creative agency Giant Spoon and fabricated by Bigger Than Life Advertising Inc. The company’s President Mark Bachman was a manager on the Empire State Building’s King Kong installation in 1983.
The “House of the Dragon” takeover included a photo opportunity with the iconic Iron Throne, a visit from the “House of the Dragon” cast, and an interactive photo booth on the 80th Floor. This partnership with Max is just one of several recent events at the Empire State Building which have garnered global attention, which include partnerships with Mercedes-AMG Petronas F1 x WhatsApp, Outward Bound, and “Star Wars.”
The Empire State Building Observatory recently underwent a $165 million reimagination that included the addition of a dedicated visitor entrance, an immersive museum with nine galleries, brand-new, bespoke Observatory Host uniforms, and a new 102nd Floor Observatory with unmatched views. The reimagined Observatory Experience has been voted the #1 attraction in the U.S. in Tripadvisor’s Travelers’ Choice Awards: Best of the Best for two consecutive years.
Tickets to see the dragon at the Empire State Building Observatory can be purchased here. Text CONNECT to 274-16 to receive real-time information about the Empire State Building’s tower lights.
Hi-res imagery and video of all elements of the House of the Dragon takeover can be found here.
About the Empire State Building
The Empire State Building, the “World's Most Famous Building," owned by Empire State Realty Trust, Inc. (ESRT: NYSE), soars 1,454 feet above Midtown Manhattan from base to antenna. The $165 million reimagination of the Empire State Building Observatory Experience creates an all-new experience with a dedicated guest entrance, an interactive museum with nine galleries, and a redesigned 102nd Floor Observatory with floor-to-ceiling windows. The journey to the world-famous 86th Floor Observatory, the only 360-degree, open-air observatory with views of New York and beyond, orients visitors for their entire New York City experience and covers everything from the building's iconic history to its current place in pop culture. The Empire State Building Observatory Experience welcomes millions of visitors each year and was declared "America's Favorite Building" by the American Institute of Architects, the world's most popular travel destination by Uber, the #1 attraction in the U.S. in Tripadvisor’s Travelers’ Choice Awards: Best of the Best for two consecutive years, and the #1 New York City attraction in Lonely Planet’s Ultimate Travel List.
Since 2011, the building has been fully powered by renewable wind electricity, and its many floors house a diverse array of office tenants such as LinkedIn and Shutterstock, as well as retail options like STATE Grill and Bar, Tacombi, and Starbucks. For more information and Observatory Experience tickets visit esbnyc.com or follow the building's Facebook, X (formerly Twitter), Instagram, Weibo, YouTube, or TikTok.
About House of the Dragon
Based on George R.R. Martin’s “Fire & Blood,” the series, set 200 years before the events of “Game of Thrones,” tells the story of House Targaryen. Co-Creator/Executive Producer George R.R. Martin; Co-Creator/Showrunner/Executive Producer, Ryan Condal; Executive Producers Sara Hess, Alan Taylor, Melissa Bernstein, Kevin de la Noy, Loni Peristere, Vince Gerardis. Season two returning cast includes Matt Smith, Olivia Cooke, Emma D’Arcy, Eve Best, Steve Toussaint, Fabien Frankel, Ewan Mitchell, Tom Glynn-Carney, Sonoya Mizuno, and Rhys Ifans. Additional returning cast includes Harry Collett, Bethany Antonia, Phoebe Campbell, Phia Saban, Jefferson Hall, and Matthew Needham. New season two cast are Abubakar Salim as Alyn of Hull, Gayle Rankin as Alys Rivers, Freddie Fox as Ser Gwayne Hightower, Simon Russell Beale as Ser Simon Strong, Clinton Liberty as Addam of Hull, Jamie Kenna as Ser Alfred Broome, Kieran Bew as Hugh, Tom Bennett as Ulf, Tom Taylor as Lord Cregan Stark, and Vincent Regan as Ser Rickard Thorne.
Source: Empire State Realty Trust
Category: Observatory
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240616631517/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom